Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07154901 · ClinicalTrials.gov registry record · Phase 1

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

A Phase 1 study of Renal Impairment, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
2
Study locations

NCT07154901 is a Phase 1 study of Renal Impairment that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 50 participants, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (52% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07154901, a Phase 1 study of Renal Impairment, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

This study is being conducted to investigate the PK, safety, and tolerability of opemalirsen in participants with renal impairment, compared to participants with normal renal function.

Conditions Studied

Renal Impairment

Interventions

  • DRUG Opemalirsen (AZD2373)

Study Locations (2)

Florida

  • Research Site - Miami
  • Research Site - Orlando

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-08-18
Est. Completion 2026-06-15
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07154901

The ClinicalTrials.gov registry entry for NCT07154901 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (52% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Opemalirsen (AZD2373) is the first listed.

NCT07154901 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT07154901 about?

NCT07154901 is a clinical study titled "Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)". This study is being conducted to investigate the PK, safety, and tolerability of opemalirsen in participants with renal impairment, compared to participants with normal renal function.

What is the current status of trial NCT07154901?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-08-18. Estimated completion is 2026-06-15.

What conditions does trial NCT07154901 study?

This clinical trial studies the following conditions: Renal Impairment.

What interventions are being tested in trial NCT07154901?

The interventions under investigation include: Opemalirsen (AZD2373) (DRUG).

Who is sponsoring clinical trial NCT07154901?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07154901 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Impairment

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.